Grace Therapeutics (GRCE) Expected to Announce Quarterly Earnings on Monday

Grace Therapeutics (NASDAQ:GRCE) is expected to be issuing its quarterly earnings data before the market opens on Monday, February 10th. Analysts expect the company to announce earnings of ($0.27) per share for the quarter.

Grace Therapeutics Trading Up 3.8 %

Shares of NASDAQ:GRCE opened at $3.30 on Monday. The stock has a market cap of $33.46 million, a price-to-earnings ratio of -3.27 and a beta of 1.43. The stock has a 50-day simple moving average of $3.78. Grace Therapeutics has a fifty-two week low of $2.13 and a fifty-two week high of $4.97.

Grace Therapeutics Company Profile

Grace Therapeutics Inc is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc, formerly known as Acasti Pharma Inc, is based in Princeton, New Jersey.